- Home
- REAL vs NKTX Comparison
REAL vs NKTX Comparison
Compare REAL & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- NKTX
- Stock Information
- Founded
- REAL 2011
- NKTX 2015
- Country
- REAL United States
- NKTX United States
- Employees
- REAL N/A
- NKTX N/A
- Industry
- REAL Other Specialty Stores
- NKTX Biotechnology: Pharmaceutical Preparations
- Sector
- REAL Consumer Discretionary
- NKTX Health Care
- Exchange
- REAL Nasdaq
- NKTX Nasdaq
- Market Cap
- REAL 871.2M
- NKTX 123.5M
- IPO Year
- REAL 2019
- NKTX 2020
- Fundamental
- Price
- REAL $10.07
- NKTX $1.95
- Analyst Decision
- REAL Strong Buy
- NKTX Strong Buy
- Analyst Count
- REAL 5
- NKTX 5
- Target Price
- REAL $11.70
- NKTX $13.50
- AVG Volume (30 Days)
- REAL 4.1M
- NKTX 502.7K
- Earning Date
- REAL 11-03-2025
- NKTX 11-06-2025
- Dividend Yield
- REAL N/A
- NKTX N/A
- EPS Growth
- REAL N/A
- NKTX N/A
- EPS
- REAL N/A
- NKTX N/A
- Revenue
- REAL $636,971,000.00
- NKTX N/A
- Revenue This Year
- REAL $14.27
- NKTX N/A
- Revenue Next Year
- REAL $9.94
- NKTX N/A
- P/E Ratio
- REAL N/A
- NKTX N/A
- Revenue Growth
- REAL 12.68
- NKTX N/A
- 52 Week Low
- REAL $2.71
- NKTX $1.31
- 52 Week High
- REAL $11.38
- NKTX $5.88
- Technical
- Relative Strength Index (RSI)
- REAL 77.50
- NKTX 40.08
- Support Level
- REAL $8.02
- NKTX $2.00
- Resistance Level
- REAL $10.35
- NKTX $2.08
- Average True Range (ATR)
- REAL 0.47
- NKTX 0.10
- MACD
- REAL 0.14
- NKTX -0.03
- Stochastic Oscillator
- REAL 90.82
- NKTX 10.26
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About NKTX Nkarta Inc.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.